CRIS Current Research Information System

FABBRI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.409
EU - Europa 2.977
AS - Asia 1.533
AF - Africa 149
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 7
Totale 9.092
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.397
GB - Regno Unito 688
CN - Cina 549
IT - Italia 523
SE - Svezia 494
DE - Germania 481
SG - Singapore 470
FR - Francia 218
IN - India 194
VN - Vietnam 191
IE - Irlanda 162
RU - Federazione Russa 114
ZA - Sudafrica 60
EE - Estonia 48
TG - Togo 47
JO - Giordania 44
AT - Austria 39
UA - Ucraina 38
CI - Costa d'Avorio 36
ID - Indonesia 31
BG - Bulgaria 30
CH - Svizzera 28
FI - Finlandia 25
NL - Olanda 19
BE - Belgio 17
HK - Hong Kong 17
PL - Polonia 13
CZ - Repubblica Ceca 10
CA - Canada 9
BR - Brasile 8
EU - Europa 7
IL - Israele 7
AU - Australia 6
GR - Grecia 6
LB - Libano 6
UZ - Uzbekistan 6
HU - Ungheria 4
JP - Giappone 4
IR - Iran 3
LT - Lituania 3
NO - Norvegia 3
PK - Pakistan 3
SC - Seychelles 3
TW - Taiwan 3
ES - Italia 2
HR - Croazia 2
NG - Nigeria 2
PA - Panama 2
PT - Portogallo 2
RO - Romania 2
SI - Slovenia 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
CL - Cile 1
DK - Danimarca 1
FK - Isole Falkland (Malvinas) 1
KR - Corea 1
MA - Marocco 1
MK - Macedonia 1
MX - Messico 1
NZ - Nuova Zelanda 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TR - Turchia 1
Totale 9.092
Salva come PNG Salva come JPEG
Città #
Fairfield 667
Southend 633
Singapore 413
Ashburn 411
Santa Clara 296
Woodbridge 286
Seattle 285
Wilmington 248
Chandler 243
Houston 228
Princeton 214
Cambridge 207
Ann Arbor 178
Dublin 161
Boardman 153
Bologna 120
Dong Ket 104
Westminster 62
San Diego 57
Nanjing 55
Padova 52
Lomé 47
Berlin 46
Amman 44
Frankfurt am Main 41
Turin 38
Abidjan 36
Shenyang 34
Jakarta 31
Milan 31
Vienna 31
Saint Petersburg 30
Sofia 29
Jinan 28
Olalla 25
Shanghai 24
Los Angeles 23
Rome 23
Bern 22
Hebei 22
Mülheim 22
Guangzhou 21
Bühl 19
Nanchang 19
Beijing 18
Helsinki 17
Paris 17
Des Moines 16
Tianjin 15
Changsha 13
Jacksonville 12
Jiaxing 12
Redmond 12
Antwerpen 11
Chicago 11
Falls Church 11
Hangzhou 11
Fuzhou 10
London 10
Hong Kong 9
Phoenix 9
Redwood City 9
Wuhan 9
Zhengzhou 9
Faenza 8
Haikou 8
Lappeenranta 8
Medford 8
Norwalk 8
Catania 7
Dearborn 7
Florence 7
Forlì 7
Lanzhou 7
Modena 7
Qingdao 7
Warsaw 7
Washington 7
Bolzano 6
Boston 6
Cesena 6
Chongqing 6
Foshan 6
Lambeth 6
Leawood 6
Occhiobello 6
Ravenna 6
Brussels 5
Chengdu 5
Kunming 5
Moscow 5
Ningbo 5
Parma 5
São Paulo 5
Toronto 5
Xi'an 5
Falkenstein 4
Hyderabad 4
Montefiore Conca 4
New York 4
Totale 6.218
Salva come PNG Salva come JPEG
Nome #
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone 219
Genetica dei comportamenti impulsivo-aggressivi: possibile applicazione in psichiatria forense? 169
Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. 160
CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: Results from the Munich Antidepressant Response Signature (MARS) study 157
Age of onset in schizophrenia spectrum disorders: Complex interactions between genetic and environmental factors 153
Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial 133
Cariprazine specificity profile in the treatment of acute schizophrenia: A meta-Analysis and meta-regression of randomized-controlled trials 133
Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: A 6-month, open-label, randomized, pilot trial 131
The comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: A 6-month, open-label, randomized controlled pilot trial 127
Progress and prospects in pharmacogenetics of antidepressant drugs 124
22q11.2 rearrangements: clinical and research implications of population-based risk of neuropsychiatric and developmental disorders 119
Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance 118
Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response 115
Clinical features and drug induced side effects in early versus late antidepressant responders. 114
A model to investigate SNPs' interaction in GWAS studies 112
Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. 109
Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study 109
Neuronal cell adhesion genes and antidepressant response in three independent samples 107
HTR1A polymorphisms and clinical efficacy of antipsychotic drug treatment in schizophrenia: A meta-analysis 105
Genome-wide association study of antidepressant response: Involvement of the inorganic cation transmembrane transporter activity pathway 105
Genetic basis of Bipolar disorder 104
Epigenetic basis of psychiatric disorders: a narrative review 103
TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. 102
Pharmacogenetics in Psychiatry 102
Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation 101
Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study 101
Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR(⁎)D. 100
Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients 100
No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. 99
Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance 99
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. 98
Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials 97
Predictors of switch from depression to mania in bipolar disorder 96
Genetics of long-term treatment outcome in bipolar disorder 96
HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in Schizophrenia 96
Pharmacogenetics in major depression: a comprehensive meta-analysis. 94
Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients 94
Mechanisms of antidepressant action: an integrated dopaminergic perspective. 93
null 93
Genetics of serotonin receptors and depression: state of the art. 93
null 92
Pharmacogenetics of antidepressants. 89
Schizophrenia-Like Symptoms in Narcolepsy Type 1: Shared and Distinctive Clinical Characteristics 89
Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. 88
Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: Common and specific effects of key regulators of fat-mass homoeostasis genes 88
Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression 88
Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. 87
Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder 87
DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy 86
Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies 86
Shared genetics among major psychiatric disorders. 85
Pharmacogenetics of antidepressant response. 84
Pharmacogenetics and depression: A critical perspective 83
Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications 80
Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials 80
Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder 80
Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder 80
null 79
Association between CANCA1C gene rs1034936 polymorphism and alcohol dependence in bipolar disorder 78
Is Pharmacogenetics Useful in Antidepressant Treatment? 77
null 74
Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression 72
The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives 71
Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice 71
The Role of Genetics in Bipolar Disorder 71
Refining prediction in treatment-resistant depression: Results of machine learning analyses in the TRD III sample 70
Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples 70
null 69
Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression 65
null 64
Precision psychiatry in clinical practice 64
Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study 64
Genetic underpinnings of sociability in the general population 64
Genetics of resilience: Implications from genome-wide association studies and candidate genes of the stress response system in posttraumatic stress disorder and depression 61
A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping 60
Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns 58
Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder 57
The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation? 57
Comparison of Mortality Rates between Italian and Foreign-born Patients with Alcohol Use Disorders 57
Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption 56
Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression 52
Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders 49
Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly 49
Genetics of treatment outcomes in major depressive disorder: Present and future 47
How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach 46
Genetic variants associated with psychotic symptoms across psychiatric disorders 45
The search for personalized antidepressant treatments: What have we learned and where are we going 45
Genetic and Environmental Contribution to Major Depressive Disorder and Self-declared Depression 44
Genetics and major depressive disorder: Clinical implications for disease risk, prognosis and treatment 42
Research domain criteria (Rdoc): A perspective to probe the biological background behind treatment efficacy in depression 42
Genetics of nonpharmacological treatments of depression 42
Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts 41
Anxiety disorders and age-related changes in physiology 39
The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs 39
Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder 39
A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response 39
Clinical, demographic, and genetic risk factors of treatment-attributed suicidality in >10,000 Australian adults taking antidepressants 38
Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression 38
New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR∗D studies: Rare variant analysis and high-density imputation 38
Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts 37
Totale 8.412
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.973
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.973
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.467 0 0 0 0 0 200 262 288 399 125 106 87
2020/2021978 193 67 34 51 39 10 27 70 119 39 24 305
2021/20221.727 122 85 82 52 154 122 48 256 75 140 311 280
2022/20231.881 170 229 118 176 111 149 111 142 344 54 164 113
2023/2024696 46 115 53 63 45 84 69 62 30 68 38 23
2024/20251.627 74 373 220 221 531 208 0 0 0 0 0 0
Totale 9.393